News

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application for ozanimod, a potential treatment for multiple sclerosis that was created at Scripps Research.

Loring, a genomics researcher and professor emeritus at Scripps Research, is also founding director of the institute’s Center for Regenerative Medicine.

Preparing a seasonal flu vaccine with the G186V mutation may prevent a vexing problem that commonly occurs during the vaccine manufacturing process.

Scripps Research scientists discover a mechanism for boosting the body's production of self-renewing T cells, offering a potential new pathway for enhancing cancer immunotherapy.

Using cryogenic electron microscopy, researchers gained crucial structural and functional insights into proton channels involved in balance, taste and yet-unidentified roles in human health.

Scripps Research analyzed pharmacy insurance claims from over 35 million Americans, finding ‘continual, marked, annual increases’ of popular brand-name drugs.

Soon after cells invented protein assembly, they faced another task crucial to survival: Disposing of incomplete protein fragments. Claudio Joazeiro, PhD, uncovers how bacteria and archaea handle recycling.

Garzone, an industry leader in translational research and clinical development, fills a critical leadership role as several of Calibr’s portfolio programs advance toward the clinic.

A protein from Simian Immunodeficiency Virus (SIV), which can infect monkeys and apes, has shown promise as a potential component of a vaccine against HIV. 

Scientists at Scripps Research have discovered that the immune system’s “natural killer” cells can actually remember old enemies, allowing them to better identify threats and hone their attack.

Nature Index has ranked Scripps Research second in the world and first in the United States among stand-alone scientific institutes for biomedical research.

Skaggs Graduate School of Chemical and Biological Sciences recognizes 50+ graduate students, the largest class in the school’s history, on May 17.

The U.S. Food and Drug Administration has approved an investigational new drug (IND) application for a phase 1/2 clinical trial of ABX196, a liver cancer therapy developed at Scripps Research.

A group of dopamine-producing neurons called PPL2 turns the volume up or down on aversive memories in the fly brain, studies from the Tomchik lab show.

Nanotube tunnels built with the help of the Rhes protein serve as bridges for the toxic Huntington’s disease protein, a new study finds.

Engle joins select group of early career faculty from nation’s top institutes to receive an unrestricted research grant of $100,000.

Cravatt is recognized for pioneering a powerful new approach for identifying protein classes based on their activity, vastly expanding the possibilities of small-molecule drug discovery.

Abide Therapeutics, Inc., a clinical-stage biopharmaceutical company founded by Scripps Research professors Benjamin Cravatt, PhD, and Dale Boger, PhD, will be acquired by the Danish pharmaceutical firm H. Lundbeck A/S (Lundbeck).

The U.S. Food and Drug Administration has approved tafamidis for the treatment of heart disease (cardiomyopathy) caused by mutant or wild-type transthyretin aggregation in adults.

Eleven students from high schools across Palm Beach County will join biomedical research laboratories at Scripps Research in Jupiter, Florida this summer as part of the institute’s 15th annual high school student internship program.

Scientists at Scripps Research have developed an experimental vaccine that may one day help treat addiction to fentanyl, a highly potent opioid linked to an epidemic of overdoses and fatalities in recent years.

There may be reason to treat severe neurodevelopmental disorders at any stage of life once options become available, a new study of SYNGAP1 related autism suggests.

Researchers at the Scripps Research Translational Institute have launched a new digital research platform called POWERMOM that enables pregnant women anywhere in the United States to contribute their health information to the study using a smartphone app.

The American Academy of Arts and Sciences, one of the world’s most prestigious honor societies, has named Scripps Research chemist Jin-Quan Yu, PhD, as an elected member of its 2019 class. Yu is known globally for his groundbreaking work in the field of organic synthetic chemistry.